09R.F Skye Bioscience, Inc.

Healthcare Biotechnology Frankfurt Exchange
0.1910 EUR
Close of Nov 11, 2026
0.6940 11.20
Market cap
EUR 846K
P/E
-
P/B
1.92x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 09R.F undervalued?

Graham number

The Graham number of Skye Bioscience, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Skye Bioscience, Inc. fundamental analysis

No fundamental analysis for Skye Bioscience, Inc. yet.

Skye Bioscience, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Skye Bioscience, Inc.

Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues wi…

Full company profile